OSR (NASDAQ:OSRH – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare OSR to similar businesses based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, risk and institutional ownership.
Analyst Ratings
This is a summary of current ratings for OSR and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
| OSR Competitors | 9916 | 15312 | 45656 | 1602 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 126.25%. Given OSR’s peers stronger consensus rating and higher possible upside, analysts clearly believe OSR has less favorable growth aspects than its peers.
Valuation & Earnings
This table compares OSR and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| OSR | $1.81 million | -$27.06 million | -0.31 |
| OSR Competitors | $688.59 million | $7.69 million | -18.81 |
OSR’s peers have higher revenue and earnings than OSR. OSR is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
OSR has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, OSR’s peers have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Profitability
This table compares OSR and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OSR | -593.15% | -8.36% | -6.24% |
| OSR Competitors | -12,224.09% | -202.33% | -31.23% |
Institutional & Insider Ownership
55.3% of OSR shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 36.9% of OSR shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
OSR beats its peers on 7 of the 13 factors compared.
OSR Company Profile
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
